PKM2 is tyrosine phosphorylated and inhibited by FGFR1 in cancer cells with oncogenic or overexpressed FGFR1. PKM2 is tyrosine phosphorylated and inhibited.

Slides:

Advertisements

Similar presentations

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

Advertisements

A novel SHP-1/Grb2–dependent mechanism of negative regulation of cytokine-receptor signaling: contribution of SHP-1 C-terminal tyrosines in cytokine signaling.

Cdc42.GTP directly activates PAK4.

A Requirement for ZAK Kinase Activity in Canonical TGF-β Signaling

RhoD Inhibits RhoC-ROCK-Dependent Cell Contraction via PAK6

PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation. PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation.

by Katriina J. Peltola, Kirsi Paukku, Teija L. T

A Requirement for ZAK Kinase Activity in Canonical TGF-β Signaling

Knock-down of endogenous PINK1 abrogates Parkin Ser65 phosphorylation.

Dual-Luciferase Activation Assay with Potential Targets of ZmbZIP22.

Volume 44, Issue 6, Pages (December 2011)

Volume 22, Issue 5, Pages (May 2012)

PDK1 regulates PLK1 in vivo and in vitro.

Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis Fumihiko Hayakawa, Martin L Privalsky

APCFZR1 promotes BRAF ubiquitination in a D-box–dependent manner.

Cytotoxicity of MSP samples to normal and cancer cell lines.

PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven.

A20 inhibits caspase-8 cleavage and TRAIL-induced apoptosis.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

PKA phosphorylates Thr63 and Ser692 to increase HIF-1α stability.

Volume 23, Issue 5, Pages (May 2013)

Downregulation of SPRY4 expression is associated with FGFR1–FRS2 activation. Downregulation of SPRY4 expression is associated with FGFR1–FRS2 activation.

The Actin-Bundling Protein Palladin Is an Akt1-Specific Substrate that Regulates Breast Cancer Cell Migration Y. Rebecca Chin, Alex Toker Molecular.

MPG is a substrate of ATM, and phosphorylation of MPG is essential for function. MPG is a substrate of ATM, and phosphorylation of MPG is essential for.

p38 MAPK activation is required for phosphorylation of Akt at Ser473.

Overexpression of HGF decreases MET protein levels.

Tyrosine phosphorylations of both DAB1 and ABL are essential for invasion of colorectal cancer cells. Tyrosine phosphorylations of both DAB1 and ABL are.

The role of SRC-C3G-RAP1 signaling in transformation induced by CRKL

ONC201 activates the ATF4 pathway through the eIF2α kinases HRI and PKR. ONC201 activates the ATF4 pathway through the eIF2α kinases HRI and PKR. (A) Western.

Characterization of the light-responsive transdermal MNs.

mTORC1- and mTORC2-activating mutations in MTOR and RHEB

Immune cell recruitment after the NIR-boosted and MN-mediated cancer immunotherapy. Immune cell recruitment after the NIR-boosted and MN-mediated cancer.

P38 activation mediates chronic insulin-induced IRS1 and IRS2 degradation and is involved in myocardial insulin resistance in vitro. p38 activation mediates.

Inhibition of BCR activation by orthogonal inhibitors of SYK-AQL.

The p53 pathway is involved in the inhibition of cell proliferation observed in 15-LOX-1-overexpressing cells. The p53 pathway is involved in the inhibition.

Immune evasion occurs through loss of TNF, IFN-γ, or antigen presentation pathways. Immune evasion occurs through loss of TNF, IFN-γ, or antigen presentation.

CO inhibits H2S generation through sGC-dependent cGMP production.

Global analysis of RV[S/T]F motif phosphorylation during mitosis.

Inhibition of CDK9 by UNC drives MYC loss.

Volume 12, Issue 3, Pages (September 2007)

MYC degradation screen identifies a compound that stabilizes MYC protein. MYC degradation screen identifies a compound that stabilizes MYC protein. (A)

CD151-knockdown cells show an aberrant spreading response to PMA

BCR–ABL kinase activity rewires GM-CSFR signaling and confers oncogene addiction in TF1 cells. BCR–ABL kinase activity rewires GM-CSFR signaling and confers.

by Emilie Clement, Hiroyuki Inuzuka, Naoe T

Fig. 3 Proteomic analysis and Western blot analysis of protein cargos of various EVs. Proteomic analysis and Western blot analysis of protein cargos of.

AG1024 reduced the level of tyrosyl-phosphorylated proteins, including Erk2. AG1024 reduced the level of tyrosyl-phosphorylated proteins, including Erk2.

Inhibition of TGF-β signaling abrogates the conversion of glutamine-deprived CD4+ T cells to Treg cells but cannot support TH1 cell generation. Inhibition.

Selective delivery of pIC/PPHAffibody decreases the survival of HER2-overexpressing cells. Selective delivery of pIC/PPHAffibody decreases the survival.

Down-regulation of the erbB-2 receptor by trastuzumab decreases Akt kinase activation but not MAPK activation. Down-regulation of the erbB-2 receptor by.

Fig. 8 C9orf72 knockdown results in an increase in autophagic flux.

by Kevin J. Paavola, Harwin Sidik, J

Discovery of Gö6976-related potent reversible EGFR T790M inhibitors.

Fig. 6 Perturbation of tetrameric RAS:RAF complexes in intact cells.

Fig. 3. AD80 is active against gatekeeper mutant RETV804M cells.

Separation-of-function mutations in ATM dictate responses to DNA damage and oxidative stress. Separation-of-function mutations in ATM dictate responses.

Changes in signal transduction pathway induced by gefitinib.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

EMT alters activation of AKT and serum-independent proliferation.

UNC drives MYC protein loss.

Fig. 5 C9orf72 knockdown disrupts autophagy induction.

The effects of AZD1775 and olaparib on DNA damage response signaling.

BCR/ABL expression, tyrosine phosphorylation, and signaling in dasatinib- and imatinib-resistant cell lines and the ubiquitin inhibitor lactacystin modifies.

Differential effects of the RAF inhibitor PLX4032 in BRAF-mutant melanoma, thyroid, and colorectal cancer cell lines. Differential effects of the RAF inhibitor.

Fig. 2 Nanofibers inhibit CA IX–associated cancer cell behaviors.

MTOR kinase inhibition–induced reactivation of AKT substrates is HER2 and PI3K dependent. mTOR kinase inhibition–induced reactivation of AKT substrates.

ERM proteins promote CD44 cleavage.

I3C reduces the level of Cdc25A protein in breast cancer cells.

Phosphorylated tyrosine residues in FGFR3, FGFR3(K650E), FGFR3-TACC3, and FGFR3(K650E)-TACC3 identified by mass spectrometry analysis. Phosphorylated tyrosine.

Expression of PKM2 Y105F mutant in H1299 cells leads to decreased proliferation under hypoxic conditions, increased oxidative phosphorylation and reduced.

Fig. 5 Treatment with molecules 13, 14, and 15 decreases HIV-1 R5 infection in human macrophages. Treatment with molecules 13, 14, and 15 decreases HIV-1.

Presentation transcript:

PKM2 is tyrosine phosphorylated and inhibited by FGFR1 in cancer cells with oncogenic or overexpressed FGFR1. PKM2 is tyrosine phosphorylated and inhibited by FGFR1 in cancer cells with oncogenic or overexpressed FGFR1. (A) Schematic representation of PKM2. The six phosphorylated tyrosine residues identified in the proteomics studies are indicated. (B) Immunoblotting (WB) of 293T cell lysates for tyrosine phosphorylation of GST-PKM2 when coexpressed with the constitutively active fusion protein 8p11 ZNF198-FGFR1 PR/TK or with FGFR1 in the presence and absence of FGFR1 ligand (bFGF). (C) FGFR1 wild type (WT) but not a kinase dead (KD) mutant inhibits PKM2 enzyme activity in 293T cells (*0.01 < P < 0.05; n.s., not significant). The error bars represent the means ± SD from three independent experiments. Relative PKM2 activity was normalized to that in control 293T cells. (D) Inhibition of FGFR1 by tyrosine kinase inhibitor TKI258 (1 μM for 2 hours) results in increased PKM2 enzyme activity in leukemia KG-1a (FOP2-FGFR1), breast cancer MDA-MB-134 (FGFR1), and lung cancer H1299 cells (FGFR1) (*0.01< P < 0.05; **P < 0.01). Relative PKM2 activity was normalized to that in control cells without TKI258 treatment. Taro Hitosugi et al., Sci. Signal. 2009;2:ra73 Copyright © 2009, American Association for the Advancement of Science